Optimizing Therapeutic Drug Monitoring of Tumor Necrosis Factor-α Antagonists in Patients With Inflammatory Bowel Diseases Reply

被引：0
|
作者：
Ben-Horin, Shomron [1 ,2 ]
Ungar, Bella [1 ,2 ]
机构：
[1] Tel Aviv Univ, Sheba Med Ctr Tel Hashomer, Dept Gastroenterol, Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2016年 / 14卷 / 10期
关键词：
D O I：
10.1016/j.cgh.2016.06.005
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1509 / 1510
页数：3
相关论文
共 50 条
  • [31] Effect of Tumor Necrosis Factor-α Inhibitors on Drug-Induced Pancreatitis in Inflammatory Bowel Disease
    Stobaugh, Derrick J.
    Deepak, Parakkal
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1282 - 1287
  • [32] Tumor necrosis factor-α in inflammatory myopathies:: Pathophysiology and therapeutic implications
    Efthimiou, Petros
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2006, 36 (03) : 168 - 172
  • [33] New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases
    Nemoz, Benjamin
    Ternant, David
    Bailly, Sebastien
    Gautier-Veyret, Elodie
    Jourdil, Jean-Francois
    Bonaz, Bruno
    Stanke-Labesque, Francoise
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (04) : 722 - 728
  • [34] Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    Melmed, Gil Y.
    Irving, Peter M.
    Casteele, Niels Vande
    Kozuch, Patricia L.
    Raffals, Laura E.
    Baidoo, Leonard
    Bressler, Brian
    Devlin, Shane M.
    Jones, Jennifer
    Kaplan, Gilaad G.
    Sparrow, Miles P.
    Velayos, Fernando S.
    Ullman, Thomas
    Siegel, Corey A.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (09) : 1655 - +
  • [35] Tumor Necrosis Factor-α Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies A Controlled Study
    Angel, Kristin
    Provan, Sella Aarrestad
    Gulseth, Hanne Lovdahl
    Mowinckel, Petter
    Kvien, Tore Kristian
    Atar, Dan
    HYPERTENSION, 2010, 55 (02) : 333 - 338
  • [36] Tumour necrosis factor-α antagonists and their therapeutic applications
    Lowe, C
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (10) : 1309 - 1322
  • [37] Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease
    Roblin, Xavier
    Riviere, Pauline
    Flamant, Mathurin
    Veyrard, Pauline
    Poullenot, Fabien
    Paul, S.
    Laharie, David
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (09) : 1904 - 1909
  • [38] Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases
    Mitrev, N.
    Vande Casteele, N.
    Seow, C. H.
    Andrews, J. M.
    Connor, S. J.
    Moore, G. T.
    Barclay, M.
    Begun, J.
    Bryant, R.
    Chan, W.
    Corte, C.
    Ghaly, S.
    Lemberg, D. A.
    Kariyawasam, V.
    Lewindon, P.
    Martin, J.
    Mountifield, R.
    Radford-Smith, G.
    Slobodian, P.
    Sparrow, M.
    Toong, C.
    van Langenberg, D.
    Ward, M. G.
    Leong, R. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (11-12) : 1037 - 1053
  • [39] Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
    Papamichael, Konstantinos
    Stocco, Gabriele
    Ruiz del Agua, Ainhoa
    THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 579 - 590
  • [40] Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
    Gareb, Bahez
    Otten, Antonius T.
    Frijlink, Henderik W.
    Dijkstra, Gerard
    Kosterink, Jos G. W.
    PHARMACEUTICS, 2020, 12 (06) : 1 - 31
12345